GLP-1 and Thyroid Function: What You Need to Know

If you're taking a GLP-1 medication like Ozempic, Wegovy, or Mounjaro, you may have heard whispers about thyroid risks. Let's cut through the noise and look at what the science actually says.

What Is GLP-1 and How Does It Work?

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after eating. It tells your pancreas to release insulin, slows down digestion, and sends fullness signals to your brain. GLP-1 medications mimic this hormone, helping people with type 2 diabetes and obesity manage blood sugar and lose weight.

These medications include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda, Victoza), and dulaglutide (Trulicity).

The Thyroid Connection: What Research Shows

Here's where things get interesting. GLP-1 receptors are found in the thyroid gland, particularly in cells called C-cells that produce calcitonin. In rodent studies, long-term exposure to GLP-1 medications caused thyroid tumors. However, the relevance to humans has not been conclusively established.

What we know from human data:

• Cases of thyroid cancer have been reported in patients using GLP-1 medications, but the absolute risk appears very low

• The FDA added a boxed warning to certain GLP-1 medications about potential thyroid C-cell tumors

• Most cases occurred in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2)

Who Should Be Concerned About Thyroid Risks?

Not everyone needs to panic. The people who should be most cautious include those with:

• A personal history of medullary thyroid carcinoma (MTC)

• A family history of MTC or MEN2 syndrome

• Anyone with a genetic predisposition to thyroid cancers

If any of these apply to you, have an honest conversation with your doctor before starting GLP-1 therapy. Baseline thyroid screening (particularly calcitonin levels) may be recommended.